Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

By T. Feltes, A. Cabalka, H. Meissner, F. M. Piazza, D. Carlin, Franklin H. Top, Edward M Connor, Henry M. Sondheimer. Jornal de Pediatria, 2003

716 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (2022, background): “have been shown to be protective against hospitalization in specific high-risk populations [46, 47] and animal models have suggested utility in prophylaxis against SARS coronavirus infection [48].”